• Balaji R. Department of Pharmacology, Rajah Muthiah Medical College, Annamalai University, Chidambaram, Tamil Nadu, India
  • Sekkizhar M. Department of Pharmacology, Rajah Muthiah Medical College, Annamalai University, Chidambaram, Tamil Nadu, India
  • Asok Kumar M. Department of Pharmacology, Rajah Muthiah Medical College, Annamalai University, Chidambaram, Tamil Nadu, India
  • Nirmala P. Department of Pharmacology, Rajah Muthiah Medical College, Annamalai University, Chidambaram, Tamil Nadu, India


Objective: Drug Utilization Research (DUR) was defined by the WHO in 1977 as “The marketing, distribution, prescription, and use of drugs in a society, with special emphasis on the resulting medical, social and economic implicationsâ€. The main aim of conducting drug utilisation research is to facilitate rational use of drugs I,e the prescription of a well documented drug together with correct information at an affordable cost. Psychiatric disorders form an important public health priority among which psychotic disorders are the chief contributors to disability adjusted life years [DALYs] and are associated with high levels of health service utilization and treatment cost. Without the knowledge of how drugs are being prescribed and used it is difficult to initiate a discussion on rational drug use or to suggest measures to improve prescribing patterns. To analyse the drug utilization pattern by using standard parameters.

Methods: After getting approval from the institutional human ethics committee and consent from the patients willing to participate in this study, a total of 79 prescriptions containing atleast one antipsychotic drug was collected in one year period from patients attending psychiatric OPD. The patients were given a one month follow up and the adverse effects which arise out of therapy are noted and analysed.

Results: Out of the 79 participants, 59.49% were males and 40.51% were females. Regarding the morbidity distribution, Schizophrenia contributes to 50.63% and bipolar disorder contributes to 29.11% of diagnosis. Based on the analysis by WHO/INRUD standard guidelines, the average number of drugs and antipsychotic drugs per prescription were 3.32 and 1.38 respectively. The utilsation of antipsychotic drugs assessed by PDD/DDD ratio is equal to one for haloperidol and aripiprazole while it is less than one for other antipsychotic drugs. The adverse effects commonly encountered while treating psychotic cases are sedation, extra pyramidal symptoms, weight gain and anticholinergic side effects like constipation and urinary retention.

Conclusion: The age and morbidity distribution of the participants are similar to the outcomes of many studies. The antipsychotic drugs haloperidol and aripiprazole are utilised appropriately while there is under utilisation of other antipsychotics. The volume of use of haloperidol, olanzapine benzodiazepines should be judicious considering their adverse effects.
Keywords: Schizophrenia (SCHZ), Bipolar disorder (BPAD), Persistent delusional disorder (PDD), Mental Retardation with significant impairment of behaviour (MR/SIB), International network for rational use of drugs (INRUD)


1. WHO. International Working Group for Drug Statistics Methodology. Introduction to drug utilization research. Geneva: WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacology; 2003.
2. Gross F. Drug utilization therapy and practice. The present situation in the Federal Republic of Germany. Eur J Clin Pharmacol 1981;19:387-94.
3. Cochrane AL. Effectiveness and efficiency–random reflections on health services. London, The Nuffield Provincial Hospitals Trust; 1982.
4. Math SB, Chandrashekar CR, Bhugra D. Psychiatric epidemiology in India. Indian J Med Res 2007;126:183–92.
5. Guidelines for ATC classification and DDD assignment 2013; WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment; 2013. Available from: [Last accessed on 10 Jul 2017]
6. Pradeep Bodke, Rama Bhosle. Psychotropic drugs utilization pattern at tertiary care institute-a retrospective analysis. Int J Recent Trends Sci Technol 2014;11:400-3.
7. Patel V. Gender in Mental Health Research. Department of Gender, Women and Health Family and Community Health. World Health Organization; 2005.
8. Piparva KG, Parmar DM, Singh AP, Gajera MV, Trivedi HR. Drug utilization study of psychotropic drugs in outdoor patients in a teaching hospital. Indian J Psychological Med 2011;33:54–8.
9. R Thara, Shantha Kamath. Women and schizophrenia. Indian J Psychiatry 2015;57 (Suppl 2):S246–S251.
10. Caryl Barnes, Philip Mitchell. Considerations in the management of bipolar disorder in women. Australian New Zealand J Psychiatry 2005;39:662–73.
11. Thakkar KB, Jain MM, Billa G, Joshi A, Khobragade AA. A Drug utilization study of psychotropic drugs prescribed in the psychiatry outpatient department of a tertiary care hospital. J Clin Diagnostic Res 2013;7:2759-64.
12. Mathew P. Generic drugs: review and experiences from South India. J Family Med Primary Care 2015;4:319–23.
13. Ajoy Bera, Ashish Mukherjee. The importance of generic drugs in India. Int J Pharm Chem Biol Sci 2012;2:575-87.
14. Patricia McGettigan, Peter Roderick, Rushikesh Mahajan, Abhay Kadam, Allyson M. Pollock use of fixed dose combination (FDC) drugs in India: central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or psychotropic drugs. PLOS Medicine 2015. Doi:10.1371/journal.pmed.1001826
15. Lieberman J, Stroup T. The NIMH-CATIE schizophrenia study: what did we learn? Am J Psychiatry 2011;168:770–5.
16. Dixon L, Perkins D, Calmes C. Guideline watch: practice guideline for the treatment of patients with Schizophrenia. Am Psychiatric Association 2009. p. 1-10.
17. National Collaborating Centre for Mental Health. The nice guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. royal college of psychiatrists’ research unit. The British Psychological Society. Leicester; 2010. p. 1-17.
18. Smalbrugge M, Jongenelis LK, Pot AM, Beekman ATF, Eefsting JA. Pain among nursing home patients in the Netherlands: prevalence, course, clinical correlates, recognition and analgesic treatment–an observational cohort study. BMC Geriatrics 2007;7:3.
19. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2007;24:CD006391.
20. Ashton H. Guidelines for the rational use of benzodiazepines. Drugs 1994;48:25–40.
21. John R Geddes, David J. Miklowitz: treatment of bipolar disorder. Lancet 2013;381:1672–82.
22. Pavo Filakovic, Anamarija Petek Eric, Ivan Pozgain. New strategies in the treatment of bipolar disorder. Psychiatria Danubina 2011;23:293-9.
23. Charles Bowden, Vivek Singh. Bipolar disorders: treatment options and patient satisfaction. Neuropsychiatr Dis Treat 2006;2:149–53.
24. Leslie Miller, Mark A Riddle, David Pruitt, Al Zachik, Susan dos Reis. Antipsychotic treatment patterns and aggressive behavior among adolescents in residential facilities. J Behav Health Serv Res 2013;40:97–110.
25. Asiya Rehman Atif, Muhammad Jawed, Syed Muhammad Shahid, Shah Ali Ul Qader, Afsheen Aman. Comparison between clozapine, an atypical antipsychotic agent and haloperidol, a conventional agent used to treat schizophrenia. Academic J Clin Rev Opinions 2010;2:17-22.
26. Alexandre Gonzalez-Rodriguez, Rosa Catalan, Rafael Penades, Victoria Ruiz, Merce Torra, Miquel Bernardo, et al. Antipsychotic response in delusional disorder and schizophrenia: a prospective cohort study. Actas Esp Psiquiatr 2016;44:125-35.
27. David Cohen, Olivier Bonnot, Bodeau MS, Ange`le Consoli, Claudine Laurent. Adverse effects of second-generation antipsychotics in children and adolescents-a bayesian meta-analysis. J Clin Psychopharmacol 2012;32:3.
28. Jina Pakpoor, Mark Agius. A review of the adverse side effects associated with antipsychotics as related to their efficacy. Psychiatria Danubina 2014;26 Suppl 1:273–84.
29. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry 2007;68:1793.
30. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003;28:995-1003.
31. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97.
32. JD Wildin, BJ Pleuvry, GE Mawer, T Onon, L Millington. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol 1990;29:169-77.
33. Jacobo Mintzer, Alistair Burns. Anticholinergic side effects of drugs in elderly people. J Royal Soc Med 2000;93:457-62.
34. Lim DK, Mahendran R. Risperidone and megacolon. Singapore Med J 2002;43:530–2.
366 Views | 350 Downloads
How to Cite
R., B., S. M., A. M., and N. P. “AN OBSERVATIONAL STUDY OF DRUG UTILISATION PATTERN AND PHARMACOVIGILANCE OF ANTIPSYCHOTICS”. International Journal of Current Pharmaceutical Research, Vol. 9, no. 6, Nov. 2017, pp. 56-62, doi:10.22159/ijcpr.2017v9i6.23430.
Original Article(s)